Anticancer Drug Release System Based on Hollow Silica Nanocarriers Triggered by Tumor Cellular Microenvironments | Zendy

Shaoxin Deng | Zendy; ChengXing Cui | Zendy; Lingyao Duan | Zendy; Linfeng Hu | Zendy; Xiaoxun Yang | Zendy; Jichao Wang | Zendy; Lingbo Qu | Zendy; Yuping Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Anticancer Drug Release System Based on Hollow Silica Nanocarriers Triggered by Tumor Cellular Microenvironments

Author(s) -

Shaoxin Deng,

ChengXing Cui,

Lingyao Duan,

Linfeng Hu,

Xiaoxun Yang,

Jichao Wang,

Lingbo Qu,

Yuping Zhang

Publication year - 2020

Publication title -

acs omega

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.779

H-Index - 40

ISSN - 2470-1343

DOI - 10.1021/acsomega.0c05032

Subject(s) - nanocarriers , drug delivery , drug , mesoporous silica , targeted drug delivery , chemistry , pharmacology , anticancer drug , drug carrier , tumor microenvironment , nanotechnology , tumor cells , cancer research , materials science , mesoporous material , medicine , biochemistry , catalysis

Targeted release of anticancer drugs to tumor sites has a pivotal role in clinical oncology. pH-responsive drug delivery systems, with an intelligent and targeted release of anticancer drugs in a controllable manner based on sensitivities to the weakly acidic environments of tumor cellular microenvironments, are desirable. Herein, the design of such a pH-responsive drug delivery system is detailed using in situ amino-functionalized hollow mesoporous silica nanoparticles as carriers. The drug release behavior of the pH-responsive delivery system was evaluated under an in vitro simulation of tumor cellular microenvironments. The drug delivery system has efficient drug loadings and targeted release. Zorubicin hydrochloride releasing percentage is almost up to 100% at a buffer pH of 5.0. The drug release systems described demonstrating great potential in anticancer therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research